MA31564B1 - Inhibition par arni de l'expression du canal alpha-enac - Google Patents

Inhibition par arni de l'expression du canal alpha-enac

Info

Publication number
MA31564B1
MA31564B1 MA32484A MA32484A MA31564B1 MA 31564 B1 MA31564 B1 MA 31564B1 MA 32484 A MA32484 A MA 32484A MA 32484 A MA32484 A MA 32484A MA 31564 B1 MA31564 B1 MA 31564B1
Authority
MA
Morocco
Prior art keywords
alpha
expression
enac
canal
rnai inhibition
Prior art date
Application number
MA32484A
Other languages
English (en)
Inventor
Heeke Gino Van
Emma Hickman
Henry Luke Danahay
Pamela Tan
Anke Geick
Hans-Peter Vornlocher
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA31564B1 publication Critical patent/MA31564B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3521—Methyl

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'INVENTION CONCERNE DES COMPOSITIONS ET DES MÉTHODES PERMETTANT DE MODULER L'EXPRESSION DU CANAL ALPHA-ENAC ET, PLUS PARTICULIÈREMENT, DE RÉGULER À LA BAISSE L'EXPRESSION DU CANAL ALPHA-ENAC À L'AIDE D'OLIGONUCLÉOTIDES MODIFIÉS PAR VOIE CHIMIQUE.
MA32484A 2007-06-15 2010-01-07 Inhibition par arni de l'expression du canal alpha-enac MA31564B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07110376 2007-06-15
EP07114265 2007-08-13

Publications (1)

Publication Number Publication Date
MA31564B1 true MA31564B1 (fr) 2010-08-02

Family

ID=40130244

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32484A MA31564B1 (fr) 2007-06-15 2010-01-07 Inhibition par arni de l'expression du canal alpha-enac

Country Status (26)

Country Link
US (12) US7718632B2 (fr)
EP (7) EP2223694B1 (fr)
JP (6) JP5485146B2 (fr)
KR (2) KR101821081B1 (fr)
CN (1) CN101778941B (fr)
AR (1) AR066984A1 (fr)
AU (1) AU2008263876B2 (fr)
BR (1) BRPI0813680A8 (fr)
CA (1) CA2690674C (fr)
CL (1) CL2008001756A1 (fr)
CO (1) CO6251331A2 (fr)
CR (1) CR11136A (fr)
CU (1) CU23774A3 (fr)
EA (1) EA200901653A1 (fr)
EC (1) ECSP099794A (fr)
ES (6) ES2432157T3 (fr)
GT (1) GT200900315A (fr)
IL (1) IL202366A0 (fr)
MA (1) MA31564B1 (fr)
MX (1) MX2009013609A (fr)
PE (1) PE20090942A1 (fr)
SG (3) SG169988A1 (fr)
SV (1) SV2009003434A (fr)
TN (1) TN2009000521A1 (fr)
TW (3) TWI629063B (fr)
WO (1) WO2008152131A2 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4709545B2 (ja) * 2002-07-26 2011-06-22 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 修飾された低分子干渉ｒｎａ分子および使用方法
KR100473148B1 (ko) * 2002-11-27 2005-03-10 (주)텔리언 버스트모드 패킷 전달을 위한 정합장치 및 방법
US8765704B1 (en) 2008-02-28 2014-07-01 Novartis Ag Modified small interfering RNA molecules and methods of use
JP2008514242A (ja) * 2004-10-01 2008-05-08 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド 改変型の小さい干渉ｒｎａ分子および使用方法
AR066984A1 (es) 2007-06-15 2009-09-23 Novartis Ag Inhibicion de la expresion de la subunidad alfa del canal epitelial de sodio (enac) por medio de arni (arn de interferencia)
EP2370578A1 (fr) * 2008-11-26 2011-10-05 Merck Sharp&Dohme Corp. Inhibition véhiculée par arn interférence de l'expression du gène de canal sodique épithélial (enac) utilisant un acide nucléique interférant court (ansi)
CN103275978B (zh) * 2009-04-03 2014-10-29 百奥迈科生物技术有限公司 修饰的小干扰核酸及其制备方法
EP2756845B1 (fr) * 2009-04-03 2017-03-15 Dicerna Pharmaceuticals, Inc. Procédés et compositions pour l'inhibition spécifique de KRAS par de l'ARN double brin asymétrique
WO2010111891A1 (fr) * 2009-04-03 2010-10-07 北京大学 Molécule modifiée d'acide oligo-nucléique, procédé d'élaboration et utilisations de celle-ci
US20120207818A1 (en) * 2009-07-14 2012-08-16 Shinohara Fumikazu Composition for suppressing expression of target gene
AU2010306940A1 (en) * 2009-10-12 2012-06-07 Smith, Larry Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro
AU2010332881B2 (en) 2009-12-18 2015-01-22 Arrowhead Pharmaceuticals, Inc. Organic compositions to treat HSF1-related diseases
EP2561077B1 (fr) 2010-04-23 2016-04-13 Arrowhead Research Corporation Compositions organiques pour traiter des maladies associées à bêta-enac
US8916352B2 (en) 2011-04-08 2014-12-23 Bio-Rad Laboratories, Inc. PCR reaction mixtures with decreased non-specific activity
BR112013027070A2 (pt) 2011-04-20 2019-09-24 J Smith Larry métodos e composições para diminuir expressão de gene utilizando componentes que auto montam em células e produzem atividade de rnai
JP2014525435A (ja) 2011-09-02 2014-09-29 ノバルティス アーゲー Ｈｓｆ１関連疾患を処置するための有機組成物
EA201991102A1 (ru) 2016-11-01 2019-09-30 Эрроухед Фармасьютикалс, Инк. Альфа-v бета-6 лиганды интегрина и варианты их применения
US10590416B2 (en) 2017-07-06 2020-03-17 Arrowhead Pharmaceuticals, Inc. RNAi agents for inhibiting expression of alpha-ENaC and methods of use
JP7431728B2 (ja) * 2017-10-31 2024-02-15 アイオーニス ファーマシューティカルズ， インコーポレーテッド ＥＮａＣ発現の調節因子
UA128250C2 (uk) * 2017-11-01 2024-05-22 Ерроухед Фармасьютикалс, Інк. Ліганди інтегринів і їх застосування
CN109364248B (zh) * 2018-10-16 2021-05-18 哈尔滨医科大学 ENaC及其抑制剂在预防、缓解和/或治疗动脉粥样硬化中的应用
EP4021413A4 (fr) * 2019-08-30 2023-07-05 United States Government as Represented by The Department of Veterans Affairs Formulations liposomales de composés troponoïdes
US11957178B2 (en) 2021-11-15 2024-04-16 Apackaging Group Llc Aerosol actuator

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4426330A (en) 1981-07-20 1984-01-17 Lipid Specialties, Inc. Synthetic phospholipid compounds
US4534899A (en) 1981-07-20 1985-08-13 Lipid Specialties, Inc. Synthetic phospholipid compounds
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4837026A (en) * 1985-10-03 1989-06-06 Rajakhyaksha Vithal J Transdermal and systemic preparation and method
DE3604625C2 (de) * 1986-02-14 1994-01-20 Bmw Rolls Royce Gmbh Gasturbine
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US4920016A (en) 1986-12-24 1990-04-24 Linear Technology, Inc. Liposomes with enhanced circulation time
US5451670A (en) * 1987-12-09 1995-09-19 City Of Hope Restriction fragment length polymorphism test for haplotyping domesticated fowl
GB8824593D0 (en) 1988-10-20 1988-11-23 Royal Free Hosp School Med Liposomes
US5013566A (en) * 1988-12-19 1991-05-07 Sampson Michael James Process for obtaining improved yields from plants used for hay making by using a coating agent
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5356633A (en) 1989-10-20 1994-10-18 Liposome Technology, Inc. Method of treatment of inflamed tissues
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5665710A (en) 1990-04-30 1997-09-09 Georgetown University Method of making liposomal oligodeoxynucleotide compositions
JP3220180B2 (ja) 1991-05-23 2001-10-22 三菱化学株式会社 薬剤含有タンパク質結合リポソーム
JP3351476B2 (ja) 1993-01-22 2002-11-25 三菱化学株式会社 リン脂質誘導体及びそれを含有するリポソーム
RU2123492C1 (ru) 1993-02-19 1998-12-20 Ниппон Синяку Ко., Лтд Производные глицерина, средство для доставки физиологически активного вещества и фармацевтическая композиция
US5395619A (en) 1993-03-03 1995-03-07 Liposome Technology, Inc. Lipid-polymer conjugates and liposomes
US5540935A (en) 1993-12-06 1996-07-30 Nof Corporation Reactive vesicle and functional substance-fixed vesicle
JP3543347B2 (ja) * 1994-01-24 2004-07-14 日本油脂株式会社 点火薬造粒物の製造方法
US5543152A (en) 1994-06-20 1996-08-06 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5820873A (en) 1994-09-30 1998-10-13 The University Of British Columbia Polyethylene glycol modified ceramide lipids and liposome uses thereof
US5756122A (en) 1995-06-07 1998-05-26 Georgetown University Liposomally encapsulated nucleic acids having high entrapment efficiencies, method of manufacturer and use thereof for transfection of targeted cells
AU705644B2 (en) 1995-08-01 1999-05-27 Novartis Ag Liposomal oligonucleotide compositions
US5858397A (en) 1995-10-11 1999-01-12 University Of British Columbia Liposomal formulations of mitoxantrone
US5998203A (en) 1996-04-16 1999-12-07 Ribozyme Pharmaceuticals, Inc. Enzymatic nucleic acids containing 5'-and/or 3'-cap structures
US5994316A (en) 1996-02-21 1999-11-30 The Immune Response Corporation Method of preparing polynucleotide-carrier complexes for delivery to cells
US6218108B1 (en) 1997-05-16 2001-04-17 Research Corporation Technologies, Inc. Nucleoside analogs with polycyclic aromatic groups attached, methods of synthesis and uses therefor
US5865710A (en) * 1996-08-01 1999-02-02 Wilson-Hyde; Cynthia Step aerobic platform
CA2283293A1 (fr) 1997-03-11 1998-09-17 Yale University Procede de diagnostic et de traitement d'etats pathologiques resultant d'un transport ionique deficient tels que le pseudo-hypoaldosteronisme de type 1 (pha1)
DE69834038D1 (de) 1997-07-01 2006-05-18 Isis Pharmaceutical Inc Zusammensetzungen und verfahren zur verabreichung von oligonukleotiden über die speiseröhre
US5976849A (en) * 1998-02-05 1999-11-02 Zeneca Limited Human E3 ubiquitin protein ligase
EP1159441B8 (fr) 1999-03-10 2008-10-29 Marie Curie Cancer Care Administration de substances a des cellules
BRPI0115814B8 (pt) * 2000-12-01 2021-05-25 Europaeisches Laboratorium Fuer Molekularbiologie Embl moléculas de rna de filamento duplo, seu método de preparação e composição farmacêutica compreendendo as mesmas
WO2002092854A2 (fr) 2001-05-16 2002-11-21 Novartis Ag Genes exprimes dans le cancer du sein en tant que cibles therapeutique et de pronostic
AU2002364612A1 (en) 2001-12-31 2003-07-24 Algos Therapeutics, Inc. METHODS AND MATERIALS FOR MODULATING ENaC-BETA
JP4709545B2 (ja) * 2002-07-26 2011-06-22 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 修飾された低分子干渉ｒｎａ分子および使用方法
JP2004121218A (ja) 2002-08-06 2004-04-22 Jenokkusu Soyaku Kenkyusho:Kk 気管支喘息または慢性閉塞性肺疾患の検査方法
GB0218970D0 (en) 2002-08-14 2002-09-25 Creative Peptides Sweden Ab Fragments of Insulin c-peptide
EP1560931B1 (fr) * 2002-11-14 2011-07-27 Dharmacon, Inc. Arnsi fonctionnel et hyperfonctionnel
US20060275770A1 (en) 2002-11-27 2006-12-07 Daniel Bednarik Heart failure gene determination and therapeutic screening
BRPI0215958B1 (pt) 2002-11-29 2016-11-08 Basf Ag métodos para produção de metionina
DE10305213A1 (de) 2003-02-07 2004-08-26 Florian Prof. Dr.med. Lang Verwendung eines neuen Polymorphismus im hsgk1-Gen zur Diagnose der Hypertonie und Verwendung der sgk-Genfamilie zur Diagnose und Therapie des Long-Q/T-Syndroms
EP1608763A2 (fr) * 2003-03-31 2005-12-28 University Of Iowa Research Foundation Composes et procedes destines a ameliorer la transduction du virus raav
US7723509B2 (en) * 2003-04-17 2010-05-25 Alnylam Pharmaceuticals IRNA agents with biocleavable tethers
WO2004094636A1 (fr) 2003-04-24 2004-11-04 Galapagos Genomics N.V. Constructions demontables effectives d'arnsi
US20050256071A1 (en) * 2003-07-15 2005-11-17 California Institute Of Technology Inhibitor nucleic acids
JP4530335B2 (ja) * 2004-02-03 2010-08-25 独立行政法人科学技術振興機構 膀胱に発現する上皮型ナトリウムチャネルに対する阻害薬
WO2005116204A1 (fr) * 2004-05-11 2005-12-08 Rnai Co., Ltd. Polynucléotide provoquant l'interférence rna et procédé de regulation d'expression génétique avec l’usage de ce dernier
SE0402832D0 (sv) * 2004-11-18 2004-11-18 Astrazeneca Ab Methods
US20060166234A1 (en) * 2004-11-22 2006-07-27 Barbara Robertson Apparatus and system having dry control gene silencing compositions
AU2005316384B2 (en) * 2004-12-14 2012-02-09 Alnylam Pharmaceuticals, Inc. RNAi modulation of MLL-AF4 and uses thereof
JP5336853B2 (ja) * 2005-11-02 2013-11-06 プロチバ バイオセラピューティクス インコーポレイティッド 修飾ｓｉＲＮＡ分子およびその使用法
US20070149456A1 (en) * 2005-12-13 2007-06-28 University Of Pittsburgh Epithelial sodium channel inhibiting agents and uses therefor
JP5274461B2 (ja) 2006-08-18 2013-08-28 アローヘッド リサーチ コーポレイション ポリヌクレオチドのインビボ送達のためのポリ結合体
EP2087110A2 (fr) 2006-10-11 2009-08-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Cibles de la grippe
AR066984A1 (es) 2007-06-15 2009-09-23 Novartis Ag Inhibicion de la expresion de la subunidad alfa del canal epitelial de sodio (enac) por medio de arni (arn de interferencia)

Also Published As

Publication number Publication date
KR20100039335A (ko) 2010-04-15
SG10201601846VA (en) 2016-04-28
BRPI0813680A8 (pt) 2018-08-28
US20100216972A1 (en) 2010-08-26
US10544418B2 (en) 2020-01-28
GT200900315A (es) 2011-10-05
US20160376599A1 (en) 2016-12-29
SV2009003434A (es) 2011-03-23
TN2009000521A1 (en) 2011-03-31
ES2439277T3 (es) 2014-01-22
TW201636027A (zh) 2016-10-16
TW201524510A (zh) 2015-07-01
EP2224004A1 (fr) 2010-09-01
US20200157550A1 (en) 2020-05-21
US9074212B2 (en) 2015-07-07
US20100210514A1 (en) 2010-08-19
JP6680728B2 (ja) 2020-04-15
CA2690674C (fr) 2018-09-11
JP5485146B2 (ja) 2014-05-07
KR101821081B1 (ko) 2018-01-23
EP2223693B1 (fr) 2013-07-24
AU2008263876B2 (en) 2012-04-12
ES2432158T3 (es) 2013-12-02
WO2008152131A3 (fr) 2009-05-28
TWI629063B (zh) 2018-07-11
MX2009013609A (es) 2010-01-20
JP6193906B2 (ja) 2017-09-06
EP2224004B1 (fr) 2013-07-24
EP2223695B1 (fr) 2013-07-24
PE20090942A1 (es) 2009-08-05
US20100210513A1 (en) 2010-08-19
EP2171059A2 (fr) 2010-04-07
KR20160105530A (ko) 2016-09-06
US20220235361A1 (en) 2022-07-28
JP2010530369A (ja) 2010-09-09
US7939508B2 (en) 2011-05-10
EP2223694B1 (fr) 2013-07-24
AR066984A1 (es) 2009-09-23
CL2008001756A1 (es) 2009-02-20
CN101778941A (zh) 2010-07-14
CN101778941B (zh) 2013-05-22
US20180148726A1 (en) 2018-05-31
TWI552753B (zh) 2016-10-11
IL202366A0 (en) 2011-08-01
EP2223692A1 (fr) 2010-09-01
EP2223694A1 (fr) 2010-09-01
US7718632B2 (en) 2010-05-18
EP2223695A1 (fr) 2010-09-01
TW200911989A (en) 2009-03-16
US9476052B2 (en) 2016-10-25
ES2432644T3 (es) 2013-12-04
SG10201404955RA (en) 2014-10-30
EA200901653A1 (ru) 2010-06-30
US20090156529A1 (en) 2009-06-18
EP2224005B1 (fr) 2013-09-11
WO2008152131A2 (fr) 2008-12-18
JP2015145393A (ja) 2015-08-13
US7943592B2 (en) 2011-05-17
US20100190714A1 (en) 2010-07-29
JP2017222704A (ja) 2017-12-21
EP2223693A1 (fr) 2010-09-01
JP7157775B2 (ja) 2022-10-20
JP2020094063A (ja) 2020-06-18
CU23774A3 (es) 2012-02-15
ES2432157T3 (es) 2013-12-02
US9914927B2 (en) 2018-03-13
US20100216971A1 (en) 2010-08-26
US20220112505A1 (en) 2022-04-14
CR11136A (es) 2010-01-20
SG169988A1 (en) 2011-04-29
ES2432532T3 (es) 2013-12-04
ECSP099794A (es) 2010-01-29
KR101653008B1 (ko) 2016-08-31
CO6251331A2 (es) 2011-02-21
US20150284726A1 (en) 2015-10-08
US8119612B2 (en) 2012-02-21
US11208662B2 (en) 2021-12-28
TWI444474B (zh) 2014-07-11
US8168606B2 (en) 2012-05-01
BRPI0813680A2 (pt) 2015-01-06
JP2022188234A (ja) 2022-12-20
JP2014129373A (ja) 2014-07-10
ES2432643T3 (es) 2013-12-04
EP2224005A1 (fr) 2010-09-01
CA2690674A1 (fr) 2008-12-18
AU2008263876A1 (en) 2008-12-18
BRPI0813680B1 (pt) 2018-02-06
EP2223692B1 (fr) 2013-07-24
JP5719047B2 (ja) 2015-05-13

Similar Documents

Publication Publication Date Title
MA31564B1 (fr) Inhibition par arni de l'expression du canal alpha-enac
EA200801959A1 (ru) Высокоразветвленный полипропилен
MA33197B1 (fr) Inhibiteurs de tripeptide époxy cétone protéases cristallines
CR20110684A (es) Derivados de imidazolidin-2-ona 1,3-disustituida como inhibidores de cyp17
ATE548374T1 (de) 2'-fluor-2'-desoxytetrahydrouridine als cytidindeaminaseinhibitoren
CY1114926T1 (el) Αντισωματα και ανοσοσυζευγματα και χρησεις αυτων
MA32934B1 (fr) Combinaisons inhibitrices hsp90
CY1112558T1 (el) Ενωσεις ν-μεθυλαμινομεθυλο ισοϊνδολης και συνθεσεις που τις περιλαμβανουν και μεθοδοι χρησης τους
DE602007012559D1 (de) H die schleimhaut
MY162157A (en) Substituted indole mcl-1 inhibitors
CR10680A (es) Composiciones de inhibidores de chk1
EA200971068A1 (ru) Триазолиламинопиримидиновые соединения
EA201100093A1 (ru) Тиадиазолилоксифениламидины и применение их в качестве фунгицидов
CY1110943T1 (el) Νεα μεθοδος διαχωρισμου των εναντιομερων του (3,4-διμεθοξυδικυκλο[4.2.0]οκτα-1,3,5-τριεν-7-υλ) νιτριλιου και εφαρμογη στη συνθεση της ιβαβραδινης
BRPI0814772A2 (pt) Indazóis substituídos por 5-piridinona
EA201170640A1 (ru) Дизамещенные фталазины-антагонисты сигнального пути hedgehog
WO2007100777A3 (fr) Méthodes pour le traitement du tdah et de troubles apparentés
MY156691A (en) 2-(r)-2-methylpyrrolidin-2-yl)-1h-benzimidazole-4-carboxamide crystalline from 1
FR2905600B1 (fr) Traitement des vertiges par l'acetyl-l-leucine.
TR201109686T2 (tr) Olmesartan'ın Farmasötik Bileşimleri.
DE602008005930D1 (de) 3-(2,2,2-trimethylhydrazinium) propionat-salze zur behandlung des myokardinfarktes
ATE479691T1 (de) 4,5,6,7-tetrahydrothienoä2,3-cüpyridine als h3- modulatoren
MX2009010812A (es) Derivados 4-dodeceno como ingredientes aromatizantes.
WO2009151618A3 (fr) Procédés et compositions pour traiter la maladie d'alzheimer
MY158406A (en) Anti bone-loss and anti attachment-loss effects of an oral composition